Rallybio (RLYB) Competitors $0.50 -0.02 (-4.39%) As of 02:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RLYB vs. VTGN, GNTA, RPTX, IRD, ANEB, IKNA, KLTO, CNTX, ASRT, and FBRXShould you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include VistaGen Therapeutics (VTGN), Genenta Science (GNTA), Repare Therapeutics (RPTX), Opus Genetics (IRD), Anebulo Pharmaceuticals (ANEB), Ikena Oncology (IKNA), Klotho Neurosciences (KLTO), Context Therapeutics (CNTX), Assertio (ASRT), and Forte Biosciences (FBRX). These companies are all part of the "pharmaceutical products" industry. Rallybio vs. Its Competitors VistaGen Therapeutics Genenta Science Repare Therapeutics Opus Genetics Anebulo Pharmaceuticals Ikena Oncology Klotho Neurosciences Context Therapeutics Assertio Forte Biosciences VistaGen Therapeutics (NASDAQ:VTGN) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment. Is VTGN or RLYB more profitable? Rallybio has a net margin of -5,682.19% compared to VistaGen Therapeutics' net margin of -6,777.08%. VistaGen Therapeutics' return on equity of -58.88% beat Rallybio's return on equity.Company Net Margins Return on Equity Return on Assets VistaGen Therapeutics-6,777.08% -58.88% -52.38% Rallybio -5,682.19%-72.31%-64.78% Which has more volatility & risk, VTGN or RLYB? VistaGen Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.17, suggesting that its stock price is 217% less volatile than the S&P 500. Do analysts rate VTGN or RLYB? Rallybio has a consensus price target of $10.00, indicating a potential upside of 1,896.01%. Given Rallybio's higher probable upside, analysts plainly believe Rallybio is more favorable than VistaGen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VistaGen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Rallybio 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better earnings and valuation, VTGN or RLYB? VistaGen Therapeutics has higher earnings, but lower revenue than Rallybio. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVistaGen Therapeutics$486K189.59-$51.42M-$1.66-1.90Rallybio$640K32.57-$57.78M-$1.09-0.46 Does the media refer more to VTGN or RLYB? In the previous week, VistaGen Therapeutics had 1 more articles in the media than Rallybio. MarketBeat recorded 2 mentions for VistaGen Therapeutics and 1 mentions for Rallybio. Rallybio's average media sentiment score of 1.89 beat VistaGen Therapeutics' score of 0.94 indicating that Rallybio is being referred to more favorably in the news media. Company Overall Sentiment VistaGen Therapeutics Positive Rallybio Very Positive Do insiders & institutionals believe in VTGN or RLYB? 78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 1.3% of VistaGen Therapeutics shares are owned by company insiders. Comparatively, 8.7% of Rallybio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryVistaGen Therapeutics and Rallybio tied by winning 8 of the 16 factors compared between the two stocks. Get Rallybio News Delivered to You Automatically Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RLYB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLYB vs. The Competition Export to ExcelMetricRallybioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.85M$3.04B$5.71B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E Ratio-0.4621.1328.0720.02Price / Sales32.57338.95459.47103.02Price / CashN/A43.2336.5558.97Price / Book0.348.278.615.88Net Income-$57.78M-$55.19M$3.24B$258.50M7 Day Performance16.51%5.50%3.83%2.03%1 Month Performance42.94%17.25%10.40%12.52%1 Year Performance-62.33%4.61%34.13%19.07% Rallybio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLYBRallybio2.8947 of 5 stars$0.50-4.4%$10.00+1,896.0%-59.7%$20.85M$640K-0.4640Positive NewsVTGNVistaGen Therapeutics0.4661 of 5 stars$2.38flatN/A-26.4%$69.40M$490K-1.4340News CoverageGNTAGenenta Science2.7286 of 5 stars$3.78-4.5%$25.00+561.4%-12.1%$69.14MN/A0.007RPTXRepare Therapeutics2.668 of 5 stars$1.57+4.7%$4.50+186.6%-60.1%$67.34M$53.48M-0.52180Positive NewsIRDOpus Genetics1.6476 of 5 stars$1.11-1.8%$7.33+560.7%N/A$66.22M$10.99M-0.5314Gap UpANEBAnebulo Pharmaceuticals2.0867 of 5 stars$1.61-3.0%$5.50+241.6%+35.0%$66.15MN/A-6.194News CoverageAnalyst ForecastIKNAIkena Oncology2.9779 of 5 stars$1.37-0.7%$3.00+119.0%-18.0%$66.11MN/A-1.5970News CoverageEarnings ReportAnalyst ForecastGap UpHigh Trading VolumeKLTOKlotho NeurosciencesN/A$1.25-3.8%N/AN/A$65.88MN/A-3.47N/ACNTXContext Therapeutics3.3273 of 5 stars$0.73+9.3%$5.50+651.2%-62.5%$65.68MN/A-2.367Positive NewsASRTAssertio2.3403 of 5 stars$0.69-0.8%$2.75+301.1%-50.7%$65.68M$124.96M-2.1420Positive NewsFBRXForte Biosciences3.5143 of 5 stars$9.84-6.7%$61.00+519.9%+46,966.5%$64.75MN/A-0.605News CoverageOptions Volume Related Companies and Tools Related Companies VistaGen Therapeutics Alternatives Genenta Science Alternatives Repare Therapeutics Alternatives Opus Genetics Alternatives Anebulo Pharmaceuticals Alternatives Ikena Oncology Alternatives Klotho Neurosciences Alternatives Context Therapeutics Alternatives Assertio Alternatives Forte Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLYB) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RLYB Stock Alerts